Valuation : Madrigal Pharmaceuticals, Inc.

Market Cap 12.48B 10.76B 10.12B 9.22B 17.34B 1,184B 17.44B 120B 46.58B 602B 46.84B 45.83B 1,997B P/E 2026 *
-85.3x
P/E 2027 * 85.6x
Enterprise Value 11.95B 10.31B 9.7B 8.84B 16.61B 1,134B 16.7B 115B 44.63B 577B 44.88B 43.9B 1,913B EV / Sales 2026 *
7.83x
EV / Sales 2027 * 5.38x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week+5.22%
Current month-0.24%
1 month+15.28%
3 months+8.33%
6 months+24.70%
Current year-7.49%
1 week 507.48
Extreme 507.48
550.33
1 month 461.25
Extreme 461.25
550.33
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.85
Extreme 9.85
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/8/26 Sell

General Counsel

-664 0.0029%
15/8/26 Free

Director

1,725 0.0075%
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+5.22%+23.04%+199.28% 12.48B
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+2.55%+46.72%+90.66% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-0.25%-1.99%-10.72%+455.09% 26.6B
+0.33%-9.64%+1.95%-15.70% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%+1.66%+35.20%-18.67% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+4.12%+4.29%+52.03%+154.09% 13.54B
Average -0.02%-2.91%+47.94%+185.76% 28.85B
Weighted average by Cap. +0.13%-2.50%+45.97%+147.90%

Financials

2026 *2027 *
Net sales 1.53B 1.32B 1.24B 1.13B 2.12B 145B 2.13B 14.64B 5.7B 73.68B 5.73B 5.61B 244B 2.14B 1.85B 1.74B 1.59B 2.98B 204B 3B 20.57B 8.01B 104B 8.05B 7.88B 343B
Net income -184M -159M -149M -136M -256M -17.45B -257M -1.76B -686M -8.88B -690M -675M -29.43B 200M 173M 162M 148M 278M 18.98B 280M 1.92B 747M 9.66B 751M 735M 32.01B
Net Debt -525M -452M -426M -388M -729M -49.78B -733M -5.03B -1.96B -25.32B -1.97B -1.93B -83.96B -943M -814M -765M -697M -1.31B -89.52B -1.32B -9.05B -3.52B -45.54B -3.54B -3.46B -151B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
01/09/26 US$538.71 -0.24% 165,742
31/08/26 US$540.03 +1.17% 134,578
28/08/26 US$533.76 -1.83% 268,664
27/08/26 US$543.69 +0.89% 221,853
26/08/26 US$538.88 +5.22% 345,540
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
538.71USD
Average target price
678.06USD
Spread / Average Target
+25.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock